{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:24:42Z","timestamp":1772832282773,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.jacl.2008.08.445","type":"journal-article","created":{"date-parts":[[2008,8,24]],"date-time":"2008-08-24T08:53:28Z","timestamp":1219568008000},"page":"375-383","source":"Crossref","is-referenced-by-count":51,"title":["Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans"],"prefix":"10.1016","volume":"2","author":[{"given":"Eseng","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Gerard","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Tata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Perevozskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Semple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yale","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2008.08.445_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.08.445_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.221.8.918","article-title":"The coronary drug project","volume":"221","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.08.445_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1749-6632.1994.tb17337.x","article-title":"Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease","volume":"748","author":"Brown","year":"1995","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.jacl.2008.08.445_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jacl.2008.08.445_bib5","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.08.445_bib6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.jacl.2008.08.445_bib7","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.jacl.2008.08.445_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol."},{"key":"10.1016\/j.jacl.2008.08.445_bib9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.jacl.2008.08.445_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0006-2952(02)01220-0","article-title":"G protein-coupled receptor for nicotinic acid in mouse macrophages","volume":"64","author":"Lorenzen","year":"2002","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.jacl.2008.08.445_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med."},{"key":"10.1016\/j.jacl.2008.08.445_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00041433-199706000-00004","article-title":"Fatty acid regulation of very low density lipoprotein production","volume":"8","author":"Lewis","year":"1997","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.jacl.2008.08.445_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.ATV.13.5.629","article-title":"Substrate delivery as a determinant of hepatic apoB secretion","volume":"13","author":"Sniderman","year":"1993","journal-title":"Arterioscler Thromb."},{"key":"10.1016\/j.jacl.2008.08.445_bib14","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.jacl.2008.08.445_bib15","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1021\/jm030888c","article-title":"Pyrazole derivatives as partial agonists for the nicotinic acid receptor","volume":"46","author":"van Herk","year":"2003","journal-title":"J Med Chem."},{"key":"10.1016\/j.jacl.2008.08.445_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0165-6147(00)89032-X","article-title":"Agonist-receptor efficacy","volume":"16","author":"Kenakin","year":"1995","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.jacl.2008.08.445_bib17","doi-asserted-by":"crossref","first-page":"18028","DOI":"10.1074\/jbc.M701866200","article-title":"Nicotinic acid receptor agonists differentially activate downstream effectors","volume":"282","author":"Richman","year":"2007","journal-title":"J Biol Chem."},{"key":"10.1016\/j.jacl.2008.08.445_bib18","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1021\/jm800258p","article-title":"3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice","volume":"51","author":"Semple","year":"2008","journal-title":"J Med Chem."},{"key":"10.1016\/j.jacl.2008.08.445_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.jacl.2008.08.445_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.0954-6820.1962.tb07203.x","article-title":"The effect of nicotinic acid on the plasma free fatty acid: demonstration of a metabolic type of sympathicolysis","volume":"172","author":"Carlson","year":"1962","journal-title":"Acta Med Scand."},{"key":"10.1016\/j.jacl.2008.08.445_bib21","first-page":"114","article-title":"Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man","volume":"57","author":"Kaijser","year":"1979","journal-title":"Med Biol."},{"key":"10.1016\/j.jacl.2008.08.445_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.jacl.2008.08.445_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.1965.tb34784.x","article-title":"Inhibition of the mobilization of free fatty acids from adipose tissue","volume":"131","author":"Carlson","year":"1965","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.jacl.2008.08.445_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0368-1319(65)80080-1","article-title":"Persistence of the inhibitory effect of nicotinic acid on catecholamine-stimulated lipid mobilization during prolonged treatment with nicotinic acid","volume":"5","author":"Carlson","year":"1965","journal-title":"J Atheroscler Res."},{"issue":"suppl","key":"10.1016\/j.jacl.2008.08.445_bib25","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408007848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408007848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T07:51:08Z","timestamp":1545810668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287408007848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1933287408007848"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2008.08.445","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}